Socioeconomic- and Insurance-Based Inequities in Oncotype DX Testing and Score-Guided Treatment.

ABSTRACT:

Purpose

Personalized approaches to breast cancer treatment are increasingly guided by expensive, lab-based genomic testing like Oncotype DX (ODX) Breast Recurrence Score Test. Little is known about how socioeconomic and insurance status may affect utilization of ODX testing and subsequent ODX score-guided treatment.

Methods

This retrospective cohort study included women diagnosed with early-stage, HR+/HER2- breast cancer from 2011 to 2023 within the US-based, electronic health record (EHR)-derived, deidentified Flatiron Health Research Database. Socioeconomic status was measured by a census block-level measure of neighborhood deprivation. Insurance status was captured at the time of diagnosis. Utilization of ODX testing was compared descriptively. Age-stratified likelihood o

SUBMITTER: Williams CP 

PROVIDER: S-EPMC12718550 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature